INO
Inovio Pharmaceuticals Inc
1.20$
-2.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 75.1% | 80.4% | 71.7% | 73.9% | 67.0% | 65.4% | 87.3% | 90.4% | 90.4% | 89.6% | 86.4% | 82.3% | |
| 30.8% | 27.0% | 11.0% | 12.7% | 18.1% | 15.4% | 46.5% | 14.3% | 13.3% | 8.4% | 58.1% | 59.6% | |
| 71.0% | 76.2% | 60.3% | 68.1% | 62.0% | 62.2% | 76.3% | 80.9% | 72.6% | 85.0% | 83.1% | 78.7% | |
| 2.1% | 3.4% | 9.5% | 3.5% | 3.1% | 1.4% | 3.5% | 1.6% | 3.4% | 1.4% | 1.1% | 0.0% | |
| 0.3% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 3.5% | 3.4% | 5.2% | 9.8% | 12.2% | 8.9% | 2.1% | 3.5% | 2.2% | – | – | – | |
| 7.7% | 4.7% | 6.1% | 5.6% | 8.0% | 7.3% | 1.9% | 2.1% | 3.0% | 0.0% | – | – | |
| 3.6% | 1.8% | 4.4% | 3.2% | 3.6% | 2.6% | 0.6% | 0.5% | 0.6% | – | – | – | |
| 15.4% | 17.7% | 29.0% | 23.9% | 33.6% | 96.2% | 14.6% | 19.4% | 36.2% | 31.4% | 39.5% | 67.6% | |
| 10.7% | 14.7% | 25.2% | 18.9% | 26.9% | 22.2% | 7.7% | 13.3% | 27.8% | 24.9% | 31.2% | 58.8% | |
| 4.8% | 5.5% | 11.8% | 13.5% | – | 1.4% | 0.4% | 0.5% | 0.8% | 11.2% | 2.2% | 3.8% | |
| 1.5% | 2.1% | 4.0% | 4.5% | 8.4% | 5.3% | 0.3% | 5.6% | 6.0% | 2.7% | 5.7% | 3.5% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 53.5% | 3.5% | 3.0% | 4.8% | – | – | – | |
| 84.4% | 82.2% | 71.0% | 76.0% | 66.3% | 2.4% | 85.4% | 80.6% | 63.8% | 68.6% | 60.5% | 32.4% | |
| -251.9% | -168.9% | -250.3% | -279.5% | -473.2% | -513.9% | -167.9% | -244.0% | -426.9% | -949.4% | -1,528.5% | -2,442.7% | |
| 45.1% | 32.0% | 42.1% | 43.8% | 70.6% | 86.6% | 31.5% | 43.3% | 5.7% | 13.0% | 24.0% | 63.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.